Results 11 to 20 of about 16,542 (247)
Cicatricial Ectropion in a Patient Treated With Dupilumab
American Journal of Ophthalmology Case Reports, 2017 Purpose: To describe a case of bilateral conjunctivitis and cicatricial ectropion associated with dupilumab therapy for atopic dermatitis. Observations: Severe hyperemia of the conjunctiva and eyelid margins, as well as cicatricial ectropion, began two ...
Alexander C. Barnes +2 more
exaly +4 more sources
Conjunctivitis in patients with atopic dermatitis treated with dupilumab [PDF]
Drugs in Context, 2020 Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. Robust evidence suggests that interleukin (IL)-4 and IL- 13 are key cytokines in the immunopathogenesis of AD.
Sandra Ferreira, Tiago Torres
doaj +2 more sources
Dupilumab – a novel treatment option against allergic diseases: a state-of-the-art review
Alergologia PolskaDupilumab is a humanized, IgG4 monoclonal antibody which binds to the α subunit of interleukin 4 receptor (IL-4R) and interleukin 13 receptor (IL-13R), thereby it inhibits their action.
Klaudia Kołakowska, Maciej Czubek
doaj +2 more sources
pharma-kritik, 2020 Ein neues Biologikum, das zur systemischen Behandlung der atopischen Dermatitis eingesetzt werden kann. Dupilumab ist bisher nicht direkt mit anderen systemischen Therapien verglichen worden und verursacht sehr häufig Augensymptome ...
+7 more sources
Predicting dupilumab treatment outcome in patients with primary diffuse type 2 chronic rhinosinusitis [PDF]
, 2023 BACKGROUND Chronic rhinosinusitis with a type 2 inflammatory pattern (T2CRS) is believed to be restricted to the nose and sinuses and associated with polyps, without clear serologic markers.
Brühlmann, Catrin +15 more
core +2 more sources
Clinical and Translational Allergy, 2023 Background The patho‐mechanism of ocular surface disease (OSD) in dupilumab‐treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity ...
Roselie Achten +13 more
doaj +1 more source
Clinical & Experimental Allergy, 2019 Abstract The Th2 cytokines interleukin 4 (IL‐4) and IL‐13 and the heterodimeric IL‐4 receptor (IL‐4R) complexes that they interact with play a key role in the pathogenesis of allergic disorders. Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL‐4 receptor alpha chain (IL‐4Rα), common to both IL‐4R complexes: type 1
Hani Harb, Talal A. Chatila
openaire +2 more sources
Dupilumab-associated cicatrizing ocular disease
American Journal of Ophthalmology Case Reports, 2022 Purpose: To describe three cases of bilateral cicatrizing conjunctivitis associated with dupilumab treatment for atopic dermatitis. Observations: Case 1 is a 69 year-old male with a history of mild, stable cicatrizing conjunctivitis thought to be ...
Amit K. Reddy +4 more
doaj +1 more source
Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.
PLoS ONE, 2022 BackgroundDupilumab is a human antibody that blocks the signaling of both interleukin-4 and interleukin-13 receptors. It has been approved for the treatment of moderate-to-severe atopic dermatitis.
Sunny Park +3 more
doaj +3 more sources
Hepatology, EarlyView., 2022 IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu +20 more
wiley +1 more source